|By Marketwired .||
|May 6, 2014 03:30 AM EDT||
OKLAHOMA CITY, OK -- (Marketwired) -- 05/06/14 -- Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical stage biopharmaceutical company.
Selexys Pharmaceuticals is developing drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn's Disease and Multiple Myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale up and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.
"With this agreement, Selexys continues its longstanding relationship with Cytovance," said Dr. Scott Rollins, President and CEO of Selexys. "Cytovance has been an integral part in helping us advance our clinical trial programs. We look forward to working with the company's team of professionals on this new product for the treatment of inflammatory diseases and cancer."
"Cytovance has been a manufacturing provider for Selexys since 2010 and welcomes this new project of SELK2 drug product for Phase 1 clinical materials," said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc. "We are proud to be an established partner with Selexys and support them in finding an effective therapy for Crohn's Disease that affects nearly 500,000 patients in the U.S."
About Selexys Pharmaceuticals, Corp.
Selexys Pharmaceuticals, Corp., is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and cancer metastasis across a broad range of severe diseases. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK. For additional information about Selexys Pharmaceuticals, visit www.selexys.com.
About Cytovance Biologics, Inc.
Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities. Learn more about Cytovance Biologics at www.cytovance.com.
Cytovance Biologics, Inc.
Jul. 29, 2016 12:30 AM EDT Reads: 1,669
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Jul. 29, 2016 12:15 AM EDT Reads: 2,076
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Jul. 29, 2016 12:15 AM EDT Reads: 1,984
Jul. 28, 2016 11:45 PM EDT Reads: 1,209
Jul. 28, 2016 10:15 PM EDT Reads: 1,219
Jul. 28, 2016 10:15 PM EDT Reads: 2,219
Jul. 28, 2016 10:15 PM EDT Reads: 1,438
Jul. 28, 2016 10:00 PM EDT Reads: 1,721
Jul. 28, 2016 10:00 PM EDT Reads: 1,448
Jul. 28, 2016 10:00 PM EDT Reads: 2,097
Jul. 28, 2016 09:00 PM EDT Reads: 2,708
Jul. 28, 2016 07:15 PM EDT Reads: 1,230
Jul. 28, 2016 07:15 PM EDT Reads: 395
Jul. 28, 2016 06:45 PM EDT Reads: 1,643
Jul. 28, 2016 06:00 PM EDT Reads: 967